Anika Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Anika Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Anika Therapeutics Inc Strategy Report
- Understand Anika Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
Anika Therapeutics Inc (Anika) develops, manufactures, and markets therapeutic products for degenerative orthopedic diseases and traumatic conditions. It offers solutions for ortho-biologics, dermal, ophthalmic, surgical, and veterinary applications. Its major products include human and veterinary visco-supplementation, Joint implants, instrumentation devices, joint replacement solutions, regenerative and orthopedic surgical therapies, bone repair therapy, advanced wound care, and ophthalmic products. Its products are made from hyaluronic acid (HA) based on technology, HYAFF, which is a solid form of HA. Anika has research and manufacturing facilities in Bedford, Massachusetts. The company offers its products through distributors in the Latin America, Canada, Europe, the Middle East and Asia. Anika is headquartered in Bedford, Massachusetts, the US.
Headquarters
United States of America
Address
32 Wiggins Ave, Bedford, Massachusetts, 01730-2315
Website
anika.com
Telephone
1 781 4579000
No of Employees
345
Industry
Medical Equipment
Ticker Symbol & Exchange
ANIK (NASD)
Revenue (2022)
$156.2M
5.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-459.4%
(2022 vs 2021)
Market Cap*
$374.5M
Net Profit Margin (2022)
XYZ
-439.6%
(2022 vs 2021)
* As of and is in US$
Anika Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Orthobiologics: | Anika. Restore Active Living. |
| Orthovisc | Orthovisc |
| Monovisc | Monovisc |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In August, the company received the final 510(k) clearance from the FDA for the Integrity Implant System. |
| 2023 | Contracts/Agreements | In April, the company entered into a cooperation agreement with Caligan Partners. |
| 2020 | Acquisitions/Mergers/Takeovers | In February, the company acquired Arthrosurface Inc, a provider of joint surface and preservation solutions for active patients. |
Competitor Comparison
| Key Parameters | Anika Therapeutics Inc | Repligen Corp | Bioventus Inc | MiMedx Group Inc | Elutia Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Bedford | Waltham | Durham | Marietta | Silver Spring |
| State/Province | Massachusetts | Massachusetts | North Carolina | Georgia | Maryland |
| No. of Employees | 345 | 2,025 | 970 | 867 | 151 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Cheryl R. Blanchard, Ph.D. | Chief Executive Officer; President | Senior Management | 2020 | 58 |
| Michael Levitz | Chief Financial Officer; Treasurer; Executive Vice President | Senior Management | 2020 | 49 |
| Anne Nunes | Chief Operations Officer; Senior Vice President | Senior Management | 2023 | - |
| Robert Delp | Vice President - US Sales | Senior Management | 2022 | - |
| David Colleran | General Counsel; Executive Vice President; Secretary | Senior Management | 2020 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer